Gilead Sciences management commentary: HIV growth drives 16% rise in Q3 2026 base business sales
Bitget2026/10/29 21:34- Gilead Sciences management commentary highlighted third-quarter 2026 sales excluding Veklury of $8.2 billion, up 16%, driven by HIV, Trodelvy and Livdelzi.
- HIV sales rose 18% to $6.2 billion, reflecting higher realized prices, stronger demand and favorable inventory dynamics.
- Trodelvy sales grew 42% on stronger breast cancer demand, while competitive pressures drove an 18% decline in cell therapy sales.
- Non-GAAP diluted earnings reached $2.55 per share, reflecting higher product sales and lower acquired research expenses, partly offset by higher operating expenses.
- Management raised full-year sales guidance excluding Veklury to $30.7 billion–$31 billion, increasing the midpoint by $900 million from August.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley: AI capital expenditure may reach 10 to 15 trillions USD in the next 10 years
Morgan Stanley stated that capital expenditure in the artificial intelligence (AI) sector could reach $10-15 trillions over the next decade.
Morgan Stanley: Apple's target price lowered to $350
Autoliv completes acquisition of MCF Safety Belts
Refining profits surge and oil prices soar; Saudi Aramco Q3 profits grow by 9% and maintains a dividend of 21.9 billions USD.
Driven by rising refining profits and oil prices, Saudi Aramco's third-quarter profits increased by 9%.
Crypto prices
More
